|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.85 USD | +0.05% |
|
-0.06% | -8.45% |
Business description: Neurocrine Biosciences, Inc.
Number of employees: 2,000
Sales by Activity: Neurocrine Biosciences, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Research and Development, Commercialization, and Sale of Pharmaceuticals | 113.35Cr | 148.87Cr | 188.71Cr | 235.53Cr | 286.05Cr |
Geographical breakdown of sales: Neurocrine Biosciences, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 113.35Cr | 148.87Cr | 188.71Cr | 235.53Cr | 286.05Cr |
Executive Committee: Neurocrine Biosciences, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Gano
CEO | Chief Executive Officer | 53 | 11/10/2024 |
| Director of Finance/CFO | 47 | 01/11/2017 | |
Sanjay Keswani
CTO | Chief Tech/Sci/R&D Officer | 56 | 02/06/2025 |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 62 | 30/11/2021 |
Bill Wilson
COO | Chief Operating Officer | - | 01/03/2004 |
Composition of the Board of Directors: Neurocrine Biosciences, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Gorman
BRD | Director/Board Member | 68 | 01/01/2008 |
Richard Pops
BRD | Director/Board Member | 64 | 01/04/1998 |
| Chairman | 78 | 01/05/2011 | |
Gary Lyons
BRD | Director/Board Member | 75 | 01/02/1993 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 01/04/1999 |
Kyle Gano
BRD | Director/Board Member | 53 | 11/10/2024 |
George Morrow
BRD | Director/Board Member | 74 | 01/10/2015 |
Leslie Norwalk
BRD | Director/Board Member | 60 | 01/09/2019 |
Shalini Sharp
BRD | Director/Board Member | 51 | 03/02/2020 |
Johanna Mercier
BRD | Director/Board Member | 57 | 15/04/2021 |
Holdings: Neurocrine Biosciences, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
VOYAGER THERAPEUTICS, INC. 15.42% | 85,75,316 | 15.42% | 35 M $ |
Company details: Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
92130, San Diego
+858 617 7600
http://www.neurocrine.com
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.05% | -0.06% | +17.25% | +37.77% | 1.3TCr | |
| +0.41% | -1.91% | +21.59% | +200.16% | 88TCr | |
| +0.69% | +0.25% | +49.37% | +57.88% | 59TCr | |
| +0.81% | -2.64% | +4.57% | +42.59% | 39TCr | |
| +0.50% | -3.04% | +5.40% | +23.34% | 33TCr | |
| -0.11% | -0.54% | +19.76% | +33.02% | 30TCr | |
| +0.07% | -3.08% | +26.04% | +57.73% | 29TCr | |
| +0.58% | -1.43% | +22.06% | +7.54% | 29TCr | |
| +0.01% | -2.84% | +16.75% | +56.14% | 20TCr | |
| +0.15% | -0.97% | +30.30% | +81.85% | 18TCr | |
| Average | +0.26% | -1.63% | +21.31% | +59.80% | 34.53TCr | |
| Weighted average by Cap. | +0.28% | -1.67% | +23.26% | +84.06% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NBIX Stock
- Company Neurocrine Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition